|76.66||+0.6700||+0.88%||Vol 1.73M||1Y Perf 84.39%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||86.00||Analyst Rating||Moderate Buy 2.00|
|Potential %||12.18||Finscreener Ranking||★★★★+ 56.66|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 57.91|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 71.97|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||19.75B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||81.03||Earnings Date||28th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||28th Apr 2021|
|Estimated EPS Next Report||2.61|
|EPS Growth Next 5 Years %||15.40|
|Avg. Weekly Volume||1.78M|
|Avg. Monthly Volume||1.67M|
|Avg. Quarterly Volume||1.98M|
Hologic Inc. (NASDAQ: HOLX) stock closed at 76.66 per share at the end of the most recent trading day (a 0.88% change compared to the prior day closing price) with a volume of 1.76M shares and market capitalization of 19.75B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5814 people. Hologic Inc. CEO is Stephen P. Macmillan.
The one-year performance of Hologic Inc. stock is 84.39%, while year-to-date (YTD) performance is 5.26%. HOLX stock has a five-year performance of 111.94%. Its 52-week range is between 41.03 and 85, which gives HOLX stock a 52-week price range ratio of 81.03%
Hologic Inc. currently has a PE ratio of 14.00, a price-to-book (PB) ratio of 5.80, a price-to-sale (PS) ratio of 5.07, a price to cashflow ratio of 13.50, a PEG ratio of 2.32, a ROA of 19.19%, a ROC of 25.81% and a ROE of 48.39%. The company’s profit margin is 33.95%, its EBITDA margin is 49.00%, and its revenue ttm is $3.78 Billion , which makes it $14.67 revenue per share.
Of the last four earnings reports from Hologic Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.61 for the next earnings report. Hologic Inc.’s next earnings report date is 28th Apr 2021.
The consensus rating of Wall Street analysts for Hologic Inc. is Moderate Buy (2), with a target price of $86, which is +12.18% compared to the current price. The earnings rating for Hologic Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hologic Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hologic Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.54, ATR14 : 2.79, CCI20 : 141.51, Chaikin Money Flow : 0.11, MACD : -0.71, Money Flow Index : 77.33, ROC : 3.78, RSI : 49.72, STOCH (14,3) : 89.46, STOCH RSI : 1.00, UO : 56.44, Williams %R : -10.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hologic Inc. in the last 12-months were: Allison P. Bebo (Sold 6 100 shares of value $512 778 ), Benjamin J. Cohn (Option Excercise at a value of $709 146), Benjamin J. Cohn (Sold 26 339 shares of value $1 992 182 ), Christiana Stamoulis (Option Excercise at a value of $249 113), Christiana Stamoulis (Sold 11 146 shares of value $824 804 ), John M. Griffin (Option Excercise at a value of $1 073 940), John M. Griffin (Sold 27 806 shares of value $1 872 989 ), Karleen M. Oberton (Option Excercise at a value of $536 283), Karleen M. Oberton (Sold 15 000 shares of value $937 500 ), Kevin R. Thornal (Option Excercise at a value of $1 013 885), Kevin R. Thornal (Sold 30 757 shares of value $1 963 639 ), Peter J. Valenti (Option Excercise at a value of $550 043), Peter J. Valenti (Sold 20 986 shares of value $1 111 135 ), Sally W. Crawford (Sold 63 900 shares of value $3 322 160 ), Scott T. Garrett (Option Excercise at a value of $1 233 732), Stephen P. Macmillan (Option Excercise at a value of $4 814 551), Stephen P. Macmillan (Sold 190 996 shares of value $9 735 257 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.